WELCOME · JUNE 8–10, 2026 · NIH NATCHER CONFERENCE CENTER

    Curing the Epilepsies 2026.

    If we connected at the poster — welcome. Here's the deeper context the printed surface couldn't carry.

    Komori Care is a privacy-first contactless multimodal nocturnal monitoring platform. The work you saw on the poster is the consumer-facing user-defined alert engine — the bigger story is a Multi-PI NIH STTR Phase I application in preparation with clinical and academic research partners and a forward path toward vEEG-anchored validation in the EMU.

    Not a tracker. Not a wearable. Not a camera.

    The premise: families and patients with SUDEP risk need nightly visibility that doesn't require wearing something or pointing a camera at the bed.

    Not a tracker.

    Trackers count steps and stages. Komori watches the night and reports what actually happened — movement events, position changes, environmental conditions, plus respiratory motion on the Pro sensor suite. The full night, not a daily score.

    Not a wearable.

    Nothing on the body. Komori sits at the bedside and senses through bedding via 60 GHz radar plus ambient WiFi channel-state-information sensing. Compliance is not a problem when there is nothing to wear.

    Not a camera.

    No video. No images. The on-device microphone only records audio features — sound-event classifications; raw audio is not kept anywhere unless the user explicitly asks for it. Thermal sensing is at body-position resolution only; cannot show faces or features. The thermal feed is fully encrypted and no images are stored — only derived metrics persist. Privacy is a structural property of the architecture, not a procedural commitment.

    FOR THE NIH AUDIENCE

    What the poster couldn't carry.

    01

    Clinical research partnership (in motion).

    Multi-PI structure with clinical and academic research partners (SUDEP enhanced multimodal monitoring). A protocol amendment is in motion to add Komori's contactless modalities to an existing study. Adult EMU phasing first, with a neonate / pediatric expansion path in subsequent amendments.

    02

    NIH STTR Phase I.

    Phase I application in preparation for the September 5, 2026 receipt date — focused on contactless modality reliability and multi-modal sensor architecture, with vEEG-anchored validation in the EMU as the forward path.

    03

    Multi-AI rule-discovery methodology.

    Four LLM analyst pipelines across 68 public physiological corpora distilled to 695 top-markers → 649 retained rule records → 436 unique rule shapes → 91 build-now detector components organized into 4 multi-phase detector families. Manuscript in preparation for IEEE Signal Processing in Medicine and Biology (SPMB) 2026.

    04

    Active recruiting for sister-site investigators.

    The STTR builds toward a multi-site validation study. Komori is actively recruiting EMU partners with vEEG + sleep-staging capability. If you run an EMU and are interested in evaluating contactless modalities under an existing or new IRB protocol — let's talk.

    Why Komori exists.

    I built Komori because my twin sons were born with Group B Strep and spent time in the NICU. My wife navigates a chronic sleep struggle. I have close friends with epilepsy.

    Each one of them — and millions of families like ours — deserves the kind of nightly visibility that doesn't require strapping something to a body or pointing a camera at a bed.

    Komori is the platform I wished existed when I was sitting in the NICU watching my sons on monitors I didn't understand, in a room without the privacy I wanted, with technology that couldn't tell me what I actually needed to know.

    — Dōvy Paukstys, Founder

    Built on real ground.

    PATENTS
    2 provisional patents
    63/999,180 · 64/066,136 · ~312 informal claims
    CLINICAL RESEARCH
    Research collaboration
    Protocol amendment in motion
    FEDERAL
    NIH STTR Phase I
    Phase I application · September 2026
    PUBLICATIONS
    IEEE manuscripts
    SPMB 2026 · Sensors Letters · in preparation
    LET'S CONNECT

    Discuss research collaboration.

    If you're an EMU clinician, SUDEP-mechanism researcher, NINDS program officer, or epilepsy-research-adjacent industry partner — send an email and Dōvy will follow up within 48 hours.

    hello@komoricare.com

    Prefer to read more first?

    Visit komoricare.com →
    FDA disclosure

    Komori is a wellness product and is not a medical device. It is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for clinical care, prescribed treatment, or any safety protocol recommended by a healthcare provider. Always follow your clinician's guidance.

    Research-track collaborations referenced on this page (clinical research protocol amendment, NIH STTR Phase I application in preparation) describe forward-looking research efforts and are not claims of current clearance, indication, or clinical performance.